作为一种治疗IgA瘤病的新方法,Sibprenlimab可以中和诱导APROLIFERATIONLIGAND (APRIL) 的药物
1School of Pharmacy and Medical Sciences, Gold Coast Campus, Griffith University, Gold Coast, Queensland, Australia.
Expert opinion on biological therapy
|April 20, 2024
概括
西贝普伦利马布在治疗免疫球蛋白A (IgA) 脏病 - - 一种脏疾病方面表现有前途. 在临床试验中,这种新疗法减少了尿中的蛋白质,并稳定了功能.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫球蛋白A (IgA) 病是一种常见的免疫媒介病,与高血压和潜在的衰竭有关.
- 目前针对IgA脏病的治疗方法缺乏改变疾病的效果或延长生命的能力.
- 在患有IgA脏病的患者中观察到A增殖诱导联结体 (APRIL) 的水平升高.
研究的目的:
- 评估针对APRIL的单克隆抗体sibeprenlimab在IgA脏病患者中的疗效和安全性.
主要方法:
- 一项2期临床试验 (NCT04287985) 评估了IgA脏病患者静脉注射西布伦利马布.
- 主要疗效终点是12个月后24小时蛋白质与肌素比率的变化.
- 监测了安全性和其他疗效标志物,包括估计的淋巴细胞过率 (eGFR) 和免疫球蛋白水平.
主要成果:
- 在12个月后,sibeprenlimab显著降低了从基线开始的蛋白质与肌氨酸比率.
- 治疗导致了一些患者的临床缓解,并稳定了eGFR.
- 在没有显著不良事件或感染的情况下,观察到银河糖缺乏IgA1,IgA,IgM和IgG水平的降低.
结论:
- 西贝普伦利马布显示出作为IgA脏病变的新型疾病修饰疗法的潜力.
- 需要进一步的长期研究来证实持续的安全性和改善临床结果.
- 开发一种皮下注射配方可能为患者的方便提供优势.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
136
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
136
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
161
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
161
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Dipeptidyl Peptidase 4 Inhibitors
182
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
182
Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K


